BIE is aggressively entering the gene therapy manufacturing industry where they will genetically characterize viral vector-based products, like rAAVs. By providing methods that improve quality control, BIE will assist these companies in taking novel therapeutics to the market faster and with fewer side effects.
BIE receives FDA SBIR funding
